Corona Virus Infection, COVID-19, Vaccine
Conditions
Keywords
COVID-19, SARS-Cov-2
Brief summary
An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac) Produced by FSBSI "Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products" for Adults Aged 60 Years and Older
Detailed description
An open comparative multicenter prospective study with retrospective data.
Interventions
BIOLOGICALCoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI "Chumakov FSC R&D IBP RAS"
200 volunteers who will be vaccinated with the CoviVac vaccine three times with an interval of 21 days intramuscularly at a dose of 0.5 ml.
Sponsors
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
60 Years to 99 Years
Healthy volunteers
Yes
Inclusion criteria
Volunteers must meet the following inclusion criteria: Type of participants • Healthy volunteers or volunteers with a history of stable diseases that do not meet any of the criteria for non-inclusion in the study. Other inclusion criteria * Written informed consent of volunteers to participate in a clinical trial * Volunteers who are able to fulfill the Protocol requirements (i.e., fill out a self-observation Diary, come to control visits).
Exclusion criteria
SARS-CoV-2 infection • A case of established COVID-19 disease confirmed by PCR and/or ELISA in the last 6 months. Diseases or medical conditions * Serious post-vaccination reaction (temperature above 40 C, hyperemia or edema more than 8 cm in diameter) or complication (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions, accompanied or not accompanied by a feverish state) to any previous vaccination. * Burdened allergic history (anaphylactic shock, Quincke's edema, polymorphic exudative eczema, serum sickness in the anamnesis, hypersensitivity or allergic reactions to the introduction of any vaccines in the anamnesis, known allergic reactions to vaccine components, etc.). * Guillain-Barre syndrome (acute polyradiculitis) in the anamnesis. * The axillary temperature at the time of vaccination is more than 37.0 ° C. * Acute infectious diseases (recovery earlier than 4 weeks before vaccination) according to anamnesis. * Donation of blood or plasma (in the amount of 450 ml or more) less than 2 months before inclusion in the study. * Severe and/or uncontrolled diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, gastrointestinal tract, liver, kidneys, hematopoietic, immune systems. * Is registered at the dispensary for tuberculosis, leukemia, oncological diseases, autoimmune diseases. * Any confirmed or suspected immunosuppressive or immunodeficiency condition in the anamnesis. * Splenectomy in the anamnesis. * Neutropenia (decrease in the absolute number of neutrophils less than 1000/mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin less than 80 g/l) according to anamnesis. * Anorexia according to anamnesis. Prior or concomitant therapy * Vaccination with any vaccine carried out within 30 days before vaccination / the first dose of the studied vaccine or planned administration within 30 days after vaccination / the last dose of the studied vaccine. * Prior vaccination with an experimental or registered vaccine that may affect the interpretation of the study data (any coronavirus or SARS vaccines). * Long-term use (more than 14 days) of immunosuppressants or other immunomodulatory drugs (immunoregulatory peptides, cytokines, interferons, immune system effector proteins (immunoglobulins), interferon inducers (cycloferon) during the six months preceding the study, according to anamnesis. * Treatment with systemic glucocorticosteroids (≥ 20 mg of prednisone, or an analog, for more than 15 days during the last month). * Volunteers who received immunoglobulin preparations or blood transfusion during the last 3 months prior to the start of the study according to anamnesis. Other non-inclusion criteria • Participation in any other clinical trial within the last 3 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of development, type and association with vaccination of adverse events during the study. | 6 month | Frequency of development, type and association with vaccination of adverse events during the study. |
| Titer of specific antibodies | 21 days | The proportion of volunteers from the total number of vaccinated with the level of seroconversion (titer of specific antibodies = 4 times the baseline level) on 21 days after the course of vaccination in the reaction of viral neutralization and / or ELISA. |
| GMT on day 21 after the course of vaccination | 21 days | The proportion of volunteers with an increase in the level of immune response in the form of geometric mean titers of specific antibodies (GMT) on day 21 after the course of vaccination in the reaction of viral neutralization and / or ELISA. |
| The frequency of occurrence of clinically significant deviations from the norm of the main indicators of vital functions and laboratory parameters. | 6 month | The frequency of occurrence of clinically significant deviations from the norm of the main indicators of vital functions and laboratory parameters. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ARVI, COVID-19 | 6 month | Frequency, severity and duration of incidence of Acute respiratory diseases (ARVI, COVID-19) within six months after triple vaccination. |
Countries
Russia
Outcome results
None listed